World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
62
Citations
22554
World Ranking
10542
National Ranking
803

Angelo Paradiso publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Angelo Paradiso sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 407 publications — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Angelo Paradiso D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Angelo Paradiso sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 62 D-Index — 46th percentile

46% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Angelo Paradiso is affiliated with the National Cancer Research Institute, UK in the United Kingdom. Their research encompasses a broad spectrum of topics within medicine and biochemistry, genetics, and molecular biology, with a particular focus on oncology and molecular biology subfields.

The scientist has contributed extensively to fields such as oncology, molecular biology, genetics, infectious diseases, and reproductive medicine. Major research topics include ovarian cancer diagnosis and treatment, BRCA gene mutations in cancer, reproductive biology and fertility, as well as COVID-19 clinical and related research studies. Additional areas of study involve radiomics and machine learning in medical imaging and cancer genomics and diagnostics.

Paradiso's frequent coauthors include Nicola Silvestris, Erica Silvestris, Miriam Dellino, Giuseppe De Palma, and Simona De Summa, indicating active collaboration within these research networks.

Regarding publication venues, Paradiso often publishes in journals such as Cancers, International Journal of Molecular Sciences, Medicine, Frontiers in Oncology, and Cancer Genomics & Proteomics. These venues reflect a focus on cancer research, molecular sciences, and clinical oncology.

Their notable recent papers include:

  • Basic principles of biobanking: from biological samples to precision medicine for patients (2021), published in Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  • Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma (2022), published in Molecular Cancer
  • Breast cancer: an update on treatment-related infertility (2020), published in Journal of Cancer Research and Clinical Oncology
  • Germinal ovarian tumors in reproductive age women (2020), published in Medicine
  • Fertility Preservation in Cancer Patients During the Coronavirus (COVID-19) Pandemic (2020), published in Frontiers in Oncology

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Signatures of mutational processes in human cancer

    Ludmil B. Alexandrov;Serena Nik-Zainal;Serena Nik-Zainal;David C. Wedge;Samuel A. J. R. Aparicio

  • Multicenter Validation of a Gene Expression–Based Prognostic Signature in Lymph Node–Negative Primary Breast Cancer

    John A. Foekens;David Atkins;Yi Zhang;Fred C.G.J. Sweep

  • The complexity of targeting EGFR signalling in cancer: from expression to turnover.

    Sinto Sebastian;Jeffrey Settleman;Stephan J. Reshkin;Amalia Azzariti

  • The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin--one single nature.

    Salvador Harguindey;Gorka Orive;José Luis Pedraz;Angelo Paradiso

  • NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space.

    Giovanni Busco;Rosa A. Cardone;Maria R. Greco;Antonia Bellizzi

  • Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients

    A Paradiso;G Simone;S Petroni;B Leone

  • Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β-tubulins

    Stefania Tommasi;Anita Mangia;Rosanna Lacalamita;Antonia Bellizzi

  • Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer.

    Angelo Paradiso;A. Mangia;A. Chiriatti;S. Tommasi

  • The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy

    Yi Zhang;Anieta M. Sieuwerts;Michelle McGreevy;Graham Casey

  • Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors.

    Paola Parrella;Maria Luana Poeta;Antonietta Pia Gallo;Maria Prencipe

  • Phosphoinositide 3-Kinase Is Involved in the Tumor-specific Activation of Human Breast Cancer Cell Na+/H+Exchange, Motility, and Invasion Induced by Serum Deprivation

    Stephan J. Reshkin;Antonia Bellizzi;Valentina Albarani;Lorenzo Guerra

  • Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer.

    Rosa Divella;Antonio Mazzocca;Antonella Daniele;Carlo Sabbà

  • The NHERF1 PDZ2 Domain Regulates PKA–RhoA–p38-mediated NHE1 Activation and Invasion in Breast Tumor Cells

    Rosa A. Cardone;Antonia Bellizzi;Giovanni Busco;Edward J. Weinman;Edward J. Weinman

  • DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

    Sabine Maier;Inko Nimmrich;Thomas Koenig;Serenella Eppenberger-Castori

  • Basic principles of biobanking: from biological samples to precision medicine for patients.

    Laura Annaratone;Giuseppe De Palma;Giuseppina Bonizzi;Anna Sapino

  • Multicenter Study Using Paraffin-Embedded Tumor Tissue Testing PITX2 DNA Methylation As a Marker for Outcome Prediction in Tamoxifen-Treated, Node-Negative Breast Cancer Patients

    Nadia Harbeck;Inko Nimmrich;Arndt Hartmann;Jeffrey S. Ross

  • Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells.

    Stephan J. Reshkin;Antonia Bellizzi;Rosa Angela Cardone;Massimo Tommasino

  • A strengthening the reporting of observational studies in epidemiology (STROBE): Are HE4 and CA 125 suitable to detect a Paget disease of the vulva?

    Miriam Dellino;Giulio Gargano;Raffele Tinelli;Carmine Carriero

  • The 76-Gene Signature Defines High-Risk Patients That Benefit from Adjuvant Tamoxifen Therapy.

    Y. Zhang;A. Sieuwerts;M. McGreevy;C. Graham

Frequent Co-Authors

Nicola Silvestris
Nicola Silvestris University of Messina
Jianming Xu
Jianming Xu Zhejiang University
Dino Amadori
Dino Amadori University of Bologna
Gianluigi Giannelli
Gianluigi Giannelli Gastroenterology Hospital "Saverio de Bellis"
John A. Foekens
John A. Foekens Erasmus University Rotterdam
Maria Grazia Daidone
Maria Grazia Daidone University of Milan
Vito Michele Fazio
Vito Michele Fazio Università Campus Bio-Medico
Ioana Berindan-Neagoe
Ioana Berindan-Neagoe Iuliu Hațieganu University of Medicine and Pharmacy
Gennaro Ciliberto
Gennaro Ciliberto Magna Graecia University
Massimo Tommasino
Massimo Tommasino International Agency For Research On Cancer

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in studying Biology or Biochemistry, there are many rewarding career and education options. One path to consider is combining science with management by exploring online healthcare mba programs, which can help you move into administrative or leadership roles in hospitals and labs.

Alternatively, the healthcare industry offers specialized certifications that can lead to well-paying jobs outside of traditional lab work. Understanding the differences between ccs vs cpc credentials is important if you're considering a coding or billing pathway, as each certification comes with unique requirements, costs, and career prospects.

As a certified medical coder salary can vary depending on experience, certification, and job location, but it remains a growth area in healthcare with reliable demand. Before committing, it's valuable to look at the medical coding job outlook to weigh the pros and cons. Exploring these related online degrees and career paths can help you find the best fit for your science-based interests and goals.

Best Scientists Citing Angelo Paradiso

Trending Scientists

Recently Published Articles